Resources

Canadian Public Reimbursement Timelines

One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.

One of Innovative Medicines Canada’s guiding principles is to offer solutions that address challenges in the Canadian health system; access to new medicines is one such challenge.

We believe that information-sharing is essential to collaboratively finding solutions and ensuring the sustainability of Canadian health systems.

Toward this effort, Innovative Medicines Canada (IMC) has put together a pCPA Trends Update page to provide drug reimbursement updates and trends in Canada and OECD countries.

These resources are prepared and updated by IMC using aggregated and independently collected data. Sources include data from IQVIA International Reimbursement Comparison, Health Canada, Canadian Agency for Drugs and Technologies in Health (CADTH), Institut national d’excellence en santé et services sociaux (INESSS), pan-Canadian Pharmaceutical Alliance (pCPA), and various Canadian provincial formularies.

Trends related to time to access, volume of negations, and pCPA performance metrics are identified.

CANADIAN PUBLIC REIMBURSEMENT TIMELINES RESOURCES

November 07, 2022

Public Reimbursement Timelines: a Pandemic Snapshot

Learn more | View

pCPA timeline data

Download All

pCPA resources

Access to Medicine • November 17, 2022

Innovative Agreements Framework

Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.

Learn more | View